UPCC 03424 Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients with Relapsed or Refractory Large B-cell Lymphomas
Enrolling By Invitation
99 years and younger
All
Phase
N/A
31 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855865
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
